GlobeNewswire

NRT Accelerates Growth through Acquisition of Casino ATM Portfolio

Dela

Acquisition includes 1,500 high-volume casino ATMs and self-service devices which dispense over $5 billion annually across nearly 200 gaming properties in the United States. As a result of the acquisition, NRT now operates over 31,000 ATM devices which process more than 300 million transactions and dispense more than $20 billion annually.

LAS VEGAS, July 02, 2018 (GLOBE NEWSWIRE) -- NRT Technologies Inc. ("NRT"), has acquired the gaming ATM assets of U.S. Bank National Association ("USB"). Fifth Third Bank acted as NRT's lead arranger of a bank syndicate that includes Capital One, CIBC, and Umpqua Bank, for financing of the transaction. Terms of the agreement are not disclosed.

NRT is a global technology leader of next generation payment systems, specialized financial/marketing self-serve kiosks, and digital and mobile experiences for the gaming industry. Through this acquisition, NRT now supports ATM processing on ATM's and TITO Redemption Units ("TRU's") across nearly 300 gaming properties in the United States. NRT is now the largest ATM processor in the North America casino market, providing mission critical services to more than 750 gaming clients, including the top 25 largest global gaming operators.

In partnership with Diebold Nixdorf, NRT will be making important upgrades to the acquired ATM fleet with new state-of-the-art ATMs that will not only support traditional ATM and cash advance functions, but also provide mobile engagement through Sightline Play+ and card-less ATM features. NRT and Diebold Nixdorf have an existing partnership with the world's largest mobility provider, Kony Inc., which will enable a unified and highly personalized mobile guest experience across NRT's growing portfolio of gaming ATM and TRU devices.

As part of the transaction, NRT has secured an expanded vault cash facility ensuring high cash availability to meet the rigorous cash withdrawal demands of NRT's gaming operator customers.

"Acquiring this ATM portfolio fits within our strategy of leading in both the cash and cashless payment verticals for casinos," said John Dominelli, NRT Founder and President. "As part of this transaction, we are pleased to welcome key members of the U.S. Bank team to the NRT family. The acquisition will provide a significant boost to NRT's transaction volume while simultaneously moving NRT into a leadership position in offering advanced, non-traditional financial services through our next generation self-service ATMs and kiosks."

"NRT's payment switch technology, commitment to customer service and exciting product roadmap made it a great fit for assuming this portfolio of ATMs," said Paul Nielsen, Vice President and Managing Director of Gaming Services for U.S. Bank. "We have full confidence that NRT will continue to provide the high level of customer service and dedication that our clients have come to expect from U.S. Bank." 

"NRT and Sightline are uniquely positioned to dramatically expand the use of mobile engagement with Play+ and innovative cash access transactions," said Kirk Sanford, Sightline Payments' Founder and CEO. "This acquisition not only expands our cash access business, but it also enhances our ability to realize on NRT and Sightline's vision for revolutionizing the way gaming operators interact with their guests."

"NRT and Sightline are doing really exciting things around casino guest experiences and it is imperative they have a partner like Diebold Nixdorf that can evolve with them and provide flexibility and innovation to assist them in delivering the best customer experience," said Bruce Pierce, Vice President and General Manager Canada at Diebold Nixdorf. "Our partnership will demonstrate the expanded connected commerce capabilities and enhance the ATM experience for all casino guests."

About Diebold Nixdorf

Diebold Nixdorf, Incorporated (NYSE:DBD), is a world leader in enabling connected commerce for millions of consumers each day across the financial and retail industries. Its software-defined solutions bridge the physical and digital worlds of cash and consumer transactions conveniently, securely and efficiently. As an innovation partner for nearly all of the world's top 100 financial institutions and a majority of the top 25 global retailers, Diebold Nixdorf delivers unparalleled services and technology that are essential to evolve in an 'always on' and changing consumer landscape. Diebold Nixdorf has a presence in more than 130 countries with approximately 23,000 employees worldwide. The organization maintains corporate offices in North Canton, Ohio, USA and Paderborn, Germany. Visit www.DieboldNixdorf.com for more information.

About NRT & Sightline

On closing of the pending merger between NRT and Sightline (subject to regulatory approval), NRT Sightline will be the global leader in the design and development of enterprise platforms for the gaming industry, including current and next generation payment systems, specialized self-serve financial/marketing kiosks, big data analytics utilizing artificial intelligence and gamification, credit marker information services, and digital and mobile experiences. Through our global family of companies, we enable more than 1 billion physical and digital commerce experiences at over 750 casino properties worldwide, including the top 25 largest casino corporations.  By seamlessly combining technological innovation with strategic partnerships, our companies create the most convenient, reliable, and secure omni-channel payment ecosystem for casino operators and their guests. NRT and Sightline have been recognized with numerous industry awards, including the coveted "Most Innovative Gaming Technology Product of the Year" for our Play+(TM) cloud-based cashless funding platform. Our collective solutions are used by casinos, lotteries, race and sports, banking & retailers around the world.

For further information about this acquisition, please contact: Michael Dominelli, NRT's SVP Marketing at mdominelli@nrttech.com

For more information about Sightline or its pending merger with NRT, please contact: Omer Sattar, Sightline's EVP Strategic Relationships at osattar@sightlinepayments.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NRT Sightline via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum